Natco Pharma Ltd. News and Updates

Name: Latest research reports of Natco Pharma Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news on Natco Pharma Ltd. from all sources in a single place.

Load latest

Natco Pharma Ltd.

12 Oct 2017

822.55

1.98%

Company Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Natcos (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharma Ltd. is trading below all available SMAs

Natco Pharma Ltd.

05 Oct 2017

822.55

1.98%

Copaxone nod a booster dose for Natco

Business Standard

Settlement of patents for higher dosage can add wings

Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr

Natco Pharma Surges 20%, Partner's Drug Gets USFDA Nod

NDTV Profit | 04 Oct 2017 1 more

Natco Pharma Ltd.

03 Oct 2017, 02:44AM

822.55

1.98%

Natco Pharma to expand API facility in TN with Rs 100 cr investment

Business Standard

At a time when the pharmaceutical industry in the State are complaining lack of government support in the State, Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility and R&D in Tamil Nadu. The company is looking at investing in its existing facility, in Thiruvallur District.The company would be investing around Rs 100 crore in addition to the existing investmenbt of Rs 86.82 crore in the facility to manufacture 16 campaign products at a time, out of 42 API products and R&D activity, with a production capacity of 66.32 tonnes per annum from existing production capacity of 46.267 tonnes per annum. The proposed expansion is in a total land of 10.57 hectre in possession of the company.According to an environmental impact assessment report submitted in connection with the expansion plan, the expansion is in order to meet the growing market demand for pharmceutical products in the country.The proposed .

Number of FII/FPI investors decreased from 385 to 317 in Jun 2025 qtr

Natco Pharma Ltd.

23 Sep 2017

822.55

1.98%

Natco Pharma: Health begins at home

Business Line

Strength in the domestic market has held the company in good stead

Natco Pharma Ltd. has lost -41.26% in the last 1 Year

Natco Pharma Ltd.

05 Sep 2017

822.55

1.98%

Natco Pharma's niche portfolio an opportunity

Business Standard

The stock price correction can be considered as a good opportunity for long-term investors

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

14 Aug 2017

822.55

1.98%

Natco Pharma lines up 10 new products for domestic market

Business Line

Natco Pharma will be launching about 10 new products in the domestic branded formulations segment in the present financial year and is targeting over 20 per cent growth year-on-year.The focus will...

Natco Pharma Ltd. is trading below all available SMAs

USFDA nod may boost Natco Pharma

Business Line | 14 Aug 2017 2 more

Natco Pharma Ltd.

09 Aug 2017

822.55

1.98%

Natco Pharma dips 12% in two days post Q1 results on profit booking

Business Standard

Thus far in 2017, the stock had gained 65% against 6% fall in healthcare index till Monday.

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

09 Aug 2017

822.55

1.98%

Natco Pharmaceuticals Ltd - Result Update Q1FY18

Buy: Natco Pharma Ltd.

Edelweiss

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 428 crs, which is 5% higher than our estimates. The strong uptick in numbers has been primarily on account of incremental profit...

Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr

Natco Pharma Ltd.

09 Aug 2017

822.55

1.98%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to | 137 crore (I-direct estimate: | 109 crore) Adjusted net profit increased 96% YoY to | 93 crore (I-direct...

Natco Pharma Ltd. has lost -41.26% in the last 1 Year

Natco Pharma Ltd.

08 Aug 2017

822.55

1.98%

Natco Pharma Ltd Q1FY18 results comment

Results Update: Natco Pharma Ltd.

HDFC Securities

Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter.